Mar 19 |
NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
|
Mar 11 |
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
|
Mar 11 |
NGM Biopharmaceuticals GAAP EPS of -$0.33 misses by $0.01
|
Mar 11 |
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
|
Mar 7 |
Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season
|
Feb 26 |
NGM Bio to go private in a $135M deal with Atlas Neon
|
Feb 26 |
NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP
|
Feb 26 |
NGM to go private through deal with investment firm
|
Feb 20 |
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference
|
Jan 19 |
Looking Into NGM Biopharmaceuticals's Recent Short Interest
|